MedTrace Logo

Dose Finding Study to Treat High Phosphate Levels in the Blood.

NCT02081534 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2020-09-14

Study results available
· View outcomes & findings →

Summary

Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period

Conditions

  • Hyperphosphatemia

Interventions

DRUG

AZD1722

AZD1722, oral tablet

DRUG

Placebo

Placebo bid, double dummy technique

Sponsors & Collaborators

  • Ardelyx

    lead INDUSTRY

Principal Investigators

  • Geoffrey A Block, MD · Denver Nephrology PC, Denver, CO 80230

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States
  • Poland
  • Slovakia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02081534 on ClinicalTrials.gov